ArticleJournal of clinical biochemistry and nutrition2025
Investigation of factors associated with osteoporosis using metabolome analysis.
Article in Journal of clinical biochemistry and nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Rapid Identification of the SNP Mutation in theAnimals : an open access journal from MDPI · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis is associated with low bone mineral density and poor bone quality in patients with type 2 diabetes mellitus (T2DM). Reports on the association between serum metabolome and osteoporosis in diabetes mellitus are rare. We aimed to identify osteoporosis-related factors in patients with T2DM. This prospective observational study included 67 patients with T2DM without osteoporosis and 24 patients with T2DM with osteoporosis who were treated with teriparatide. The association between the serum metabolome at baseline and changes in bone mineral density and the bone quality of the lumbar spine and proximal femur over 1 year was evaluated. In the teriparatide-treated group, bone mineral density, young adult mean values, and trabecular bone scores (T-scores) of the lumbar spine significantly increased 1 year after baseline compared with those at baseline. Improvements in these bone assessment indices were significantly higher in the teriparatide-treated group than in the non-treated group. Baseline alkaline phosphatase, bone-specific alkaline phosphatase, and malonic acid levels were significantly negatively correlated with bone mineral density, young adult mean values, and T-scores. Changes in bone mineral density, young adult mean values, and T-score 1 year after baseline were significantly positively correlated with baseline alkaline phosphatase, bone-specific alkaline phosphatase, oxalic acid, and aspartic acid levels in the teriparatide-treated group. Serum oxalic acid and malonic acid levels may be novel markers of osteoporosis. Teriparatide may be more effective in patients with higher baseline serum oxalic acid and aspartic acid levels than in those with lower levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.